Provided by Tiger Trade Technology Pte. Ltd.

ENGENE HOLDINGS INC

1.81
+0.04002.26%
Volume:27.33K
Turnover:49.23K
Market Cap:121.24M
PE:-0.90
High:1.81
Open:1.80
Low:1.79
Close:1.77
52wk High:12.25
52wk Low:1.40
Shares:66.98M
Float Shares:32.73M
Volume Ratio:0.57
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0205
EPS(LYR):-2.2947
ROE:-60.50%
ROA:-31.99%
PB:0.53
PE(LYR):-0.79

Loading ...

enGene Therapeutics Inc. Reports Results for the Quarter Ended July 31 - Earnings Summary

Reuters
·
Sep 09

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Sep 09

enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate

Benzinga Earnings
·
Sep 08

enGene Q3 FY26 Net Loss Widens 12.11% to USD 32.5 Million

Reuters
·
Sep 08

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Sep 08

enGene Therapeutics Inc. Expected to Post a Loss of 43 Cents a Share - Earnings Preview

Reuters
·
Sep 07

enGene Therapeutics to Present at Wells Fargo Healthcare Conference

Reuters
·
Sep 01

Engene Therapeutics Files Form 3 for SVP Finance, Treasurer Kathleen P. Richton

Reuters
·
Jul 23

Engene Therapeutics - Richard Glickman Resigns as Director and Chairman of Engene Therapeutics - SEC Filing

THOMSON REUTERS
·
Jul 16

Engene Names Michael Heffernan Board Chairman as Richard Glickman Steps Down

Reuters
·
Jul 16

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

THOMSON REUTERS
·
Jul 15

enGene amends filing, lifts estimated non-cash stock-comp restructuring charge to $4.7 million-$5 million

Reuters
·
Jun 19

EnGene Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
Jun 19

enGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says

MT Newswires Live
·
Jun 18

Morgan Stanley Downgrades enGene to Underweight From Equalweight

MT Newswires Live
·
Jun 18

enGene Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 16

Engene Reports Second Quarter 2026 Financial Results And Provides Business Update

Reuters
·
Jun 15

enGene Therapeutics - Estimates $5.7-$6.4 Mln Restructuring Costs and $4.7-$5 Mln Non-Cash Stock Compensation - SEC Filing

THOMSON REUTERS
·
Jun 15

enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate

Benzinga Earnings
·
Jun 15

enGene Q2 FY26 net loss widens to USD 30.23 million

Reuters
·
Jun 15